|
DHX9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62581059726108E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.09876601945325E-13 |
| Normal-vs-Stage2 |
1.91070000044036E-07 |
| Normal-vs-Stage3 |
7.03881397612349E-14 |
| Normal-vs-Stage4 |
1.62592161956354E-12 |
| Stage1-vs-Stage2 |
7.909600E-01 |
| Stage1-vs-Stage3 |
8.478400E-02 |
| Stage1-vs-Stage4 |
6.444800E-03 |
| Stage2-vs-Stage3 |
3.928200E-01 |
| Stage2-vs-Stage4 |
1.497630E-01 |
| Stage3-vs-Stage4 |
3.584200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.99440505513849E-15 |
| Normal-vs-AfricanAmerican |
4.16960000000355E-05 |
| Normal-vs-Asian |
3.88770005077532E-09 |
| Caucasian-vs-AfricanAmerican |
2.074000E-01 |
| Caucasian-vs-Asian |
5.319200E-01 |
| AfricanAmerican-vs-Asian |
4.449000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.68753899743024E-14 |
| Normal-vs-Female |
1.66444635851803E-12 |
| Male-vs-Female |
3.131000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.46214160171121E-12 |
| Normal-vs-Age(41-60Yrs) |
4.04010158661094E-13 |
| Normal-vs-Age(61-80Yrs) |
3.08630898615547E-12 |
| Normal-vs-Age(81-100Yrs) |
2.036000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.532800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.944800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.534400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.931800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.242400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.364000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.218400E-03 |
| Classical-VS-Follicular |
4.389500E-04 |
| Classical-VS-Other |
1.100760E-01 |
| Classical-VS-Normal |
2.81075163144351E-12 |
| Tall-VS-Follicular |
8.535400E-01 |
| Tall-VS-Other |
8.317000E-01 |
| Tall-VS-Normal |
1.05319974963436E-10 |
| Follicular-VS-Other |
9.207000E-01 |
| Follicular-VS-Normal |
2.99760216648792E-14 |
| Other-VS-Normal |
9.5152999999959E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63624669369256E-12 |
| Normal-vs-N1 |
2.66453525910038E-14 |
| N0-vs-N1 |
1.083210E-01 |
|
|
